Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -233.0%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $3M | $3M | $7M | — | — | — |
| Enterprise Value | $8M | $5M | $-1514025 | $7M | — | — | — |
| P/E Ratio → | -0.31 | — | — | — | — | — | — |
| P/S Ratio | 1464.76 | 757.08 | 175.12 | 1370.11 | — | — | — |
| P/B Ratio | 13.44 | 16.05 | 0.45 | 30.60 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1190.90 | -81.40 | 1351.74 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | -2884.7% | -2884.7% | -444.2% | -476.9% | -139.7% | -72.9% | -71.8% |
| Operating Margin | -192013.1% | -192013.1% | -33902.0% | -118698.3% | -32765.6% | -10030.2% | -5949.0% |
| Net Profit Margin | -201499.5% | -201499.5% | -35511.9% | -123384.3% | -33592.6% | -9577.3% | -5938.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -233.0% | -233.0% | -175.0% | -2756.1% | — | — | -1207.8% |
| ROA | -127.7% | -127.7% | -103.3% | -236.4% | -240.4% | -126.3% | -194.9% |
| ROIC | -270.1% | -270.1% | -352.7% | — | — | -319.1% | — |
| ROCE | -202.0% | -202.0% | -137.0% | -16697.5% | — | -315.5% | -469.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 14.55 | 14.55 | 0.14 | 6.79 | — | — | 2.99 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 9.20 | -0.65 | -0.41 | — | — | 1.41 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -16.51 | -16.51 | -17.65 | -25.13 | -11.99 | -17.51 | -1354.79 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.59 | 0.59 | 4.20 | 1.47 | 0.56 | 1.47 | 1.35 |
| Quick Ratio | 0.41 | 0.41 | 3.84 | 1.10 | 0.36 | 0.80 | 0.60 |
| Cash Ratio | 0.30 | 0.30 | 3.32 | 0.91 | 0.26 | 0.65 | 0.44 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Inventory Turnover | 0.20 | 0.20 | 0.16 | 0.04 | 0.05 | 0.06 | 0.13 |
| Days Sales Outstanding | — | 365.00 | — | — | 58.94 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $938257 | $352520 | $79505 | $33189 | $33138 | $33138 |
Pre-commercial liquidity exhaustion
As reported in recent financial statements, HSCS trades at a price-to-sales ratio of 1464.76, a figure that appears disconnected from the company's negligible revenue generation and suggests that market participants are pricing the equity based on speculative R&D potential rather than any established commercial performance metrics.
The extreme P/S multiple indicates that investors are assigning value to the company's proprietary wavelet transform technology rather than its current financial output. This valuation level warrants caution, as it implies an expectation of rapid, non-linear growth that remains unproven given the company's historical inability to scale revenue.
Based on the provided quarterly data, the company's gross margin of -2884.71% highlights a cost structure that is fundamentally misaligned with its current revenue, as the firm continues to absorb significant expenses related to clinical validation and regulatory compliance without achieving the necessary volume to reach break-even.
The persistent negative operating margins suggest that the company is currently in a high-burn developmental phase where every dollar of revenue is eclipsed by the fixed costs of maintaining its AI-diagnostic infrastructure. Investors should monitor whether the shift toward a software-centric model can eventually improve these margins, though current data provides no evidence of such a transition.
According to historical financial data, the company's ROIC has consistently remained in negative territory, reaching -57.6% in 2026Q2, which indicates that the capital deployed into research and development is currently failing to generate any positive economic return for shareholders or the business itself.
The inability to generate a positive return on invested capital is a structural concern that reflects the company's reliance on external funding to sustain its operations. This trend suggests that the firm is effectively destroying capital as it attempts to navigate the regulatory and commercial hurdles inherent in the medical device industry.
As indicated by the erratic cash conversion cycle data, which shows significant volatility in days inventory outstanding, the company lacks the operational maturity to manage its working capital effectively, a common trait among firms that have not yet achieved a consistent commercial go-to-market strategy.
The extreme fluctuations in inventory and payables suggest that the company's supply chain and sales processes are not yet optimized for scale. This lack of efficiency may further exacerbate the company's cash burn, as it struggles to balance the costs of hardware production with the slow adoption of its diagnostic platform.
The most commonly misapplied metric for HSCS is the price-to-sales ratio, which obscures the company's pre-commercial status and fails to account for the fact that current revenue is likely non-recurring, making traditional valuation multiples largely irrelevant for assessing the firm's true long-term viability.
Analysts should instead focus on metrics such as cash runway and the achievement of specific regulatory milestones, which are far more indicative of the company's survival than revenue-based multiples. Relying on P/S ratios in this context may lead to a fundamental misunderstanding of the company's risk profile and its reliance on future capital raises.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HSCS stock.
HeartSciences Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
HeartSciences Inc.'s return on equity (ROE) is -233.0%. The historical average is -204.0%.
Based on historical data, HeartSciences Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
HeartSciences Inc. has -2884.7% gross margin and -192013.1% operating margin.